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ABSTRACT 
Attenuated measles virus has revealed selective tumor cell killing and is currently tested in clinical trials 
for the therapy of cancer patients. The amount of infectious particles per dose needed for oncolytic 
therapy can be more than a million times higher compared to vaccination. This requires highly effective 
production processes which guarantee the measles virus quantities needed for its use in cancer therapy. 
Referring to measles virus production itself, several factors are influencing process parameters and 
subsequent virus yields. These factors are medium optimization, feeding of nutrients, an optimal 
multiplicity of infection, localization of produced virus particles, temperature sensitivity and time of 
harvest. This review summarizes the available data concerning measles virus production in cell culture 
and factors influencing the virus yield.  
 
Keywords: Measles Virus (MV), Subacute Sclerosing Panencephalitis (SSPE), Major Complement Protein 
(MCP), Cytopathic Effect (CPE) 
1. INTRODUCTION 
 Measles is a highly infectious disease of the 
respiratory and lymphoid systems caused by Measles 
Virus (MV). Beside the typical rash and Koplik spots, this 
disease is clinically characterized by high fever and a 
considerably weakened state of health due to transient, 
distinct immune suppression. The course of disease is 
often relatively mild, but sometimes life-threatening. 
Deadly complications such as e.g., severe pneumonia or 
Subacute Sclerosing Panencephalitis (SSPE) occur with a 
fatality rate of about 1 in 1,000 patients (Sabella, 2010). 
Especially the life-threatening direct ethiophatology of 
measles can be prevented by vaccination using life-
attenuated vaccine strains of MV. These vaccines have 
been used in millions of doses up to now, probably 
evoking life-long immunity and revealing an excellent 
safety profile. Derivatives of these vaccine strains are used 
in current clinical trials for their efficacy in oncolytic 
virotherapy (Msaouel et al., 2011).  
 The only natural hosts for MV are humans or non-
human primates. MV as a member of the order 
Mononegavirales is an envelope, single-stranded, negative-
sense RNA virus from the family Paramyxoviridae (genus 
Morbillivirus) (Navaratnarajah et al., 2009). The virus is 
found as pleomorphic particles with a size of 120-270 nm. 
The two glycoproteins hemagglutinin (H   protein) and 
fusion protein  (F protein)    are   embedded   in   the 
lipid    bilayer   constituting    the    viral   envelope. 
The matrix protein (M protein) covers the inner side of the 
viral envelope and modulates the activity of the viral 
glycoproteins (Cathomen et al., 1998). The viral RNA is 
encased in a ribonucleocapsid structure. The 
ribonucleocapsid consists of the nucleocapsid protein 
tightly wrapping the RNA genome and the associated viral 
polymerase (L) and viral Phosphoprotein (P), a co-factor 
of the polymerase (Fig. 1A). The attachment protein of 
MV, the H protein, exhibits no neuraminidase activity, as 
already indicated by its name, nor does it adsorb to 
neuraminic acid as entry receptor, which is otherwise 
typical for paramyxoviral attachment proteins of other 
genera (Navaratnarajah et al., 2009). 
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Fig. 1. Particle structure and replication cycle of MV. A: MV is a single-stranded RNA virus. Viral RNA is encapsulated by a viral 
nucleocapsid. The glycoproteins haemagglutinin (H protein) and fusion protein (F protein) are embedded in the lipid layer. 
The matrix protein (M-protein) covers the inner side of the viral envelope and interacts with viral glycoproteins and the 
ribonucleocapsid. B: MV attaches to the host cell membrane via the viral H protein binding to one of the three receptors 
SLAM, CD46, or nectin-4 (step 1). After receptor attachment, H is thought to trigger the associated F protein, resulting in 
fusion of viral and host cell membranes (step 2) with the formation of a fusion pore, through which the ribonucleoprotein 
complex enters the cells´ cytoplasm (step 3). Viral RNA polymerase uses ribonucleotide triphosphates in the cytosol to 
transcribe the viral genome into viral mRNAs (step 4) and, after translation of viral proteins (step 5), subsequently to replicate 
the viral RNA genome and antigenome (step 6). Together with the replicated viral genome, the N, P and L proteins assemble 
a progeny ribonucleocapsid (step 7). H protein and F protein, the viral transmembrane glycoproteins, are produced at the 
ribosomes of the rough ER (step 8). These two proteins are transported as oligomeric complexes to the cell membrane via the 
Golgi apparatus utilizing the exocytotic pathway (step 9). The progeny ribonucleocapsid associates at the plasma membrane 
of the host cell with the viral transmembrane glycoproteins, mediated by the M protein. Direct association of the M protein 
with the cytoplasmic domains of the H and F proteins is supposed to induce folding of the cell membrane, followed by the 
release of the virus particle by budding (step 10). C: Infected cells fuse with neighboring receptor-positive cells resulting in 
multi-nucleated giant cells (syncytia). 
 
The H and the F proteins mediate MV cell entry at the 
cell surface via fusion of the viral lipid envelope bilayer 
and the host cell cytoplasmic membrane (Fig. 1B). The 
H protein binds to specific host cell receptors and is 
thought to trigger the F protein via conformational 
changes to initiate the fusion between the virus´ and the 
cells´ membranes. Three main receptors are used by 
MV. Pathogenic wild-type strains of MV utilize 
signaling lymphocyte activation molecule 
(SLAM / CD150) (Tatsuo et al., 2000) on activated 
immune cells and nectin-4/ PVRL-4 (Mühlebach et al., 
2011; Noyce et al., 2011) on epithelial cells as 
receptors. The vaccine strain has expanded its receptor 
specificity and additionally uses CD46, i.e., Major 
Complement Protein (MCP) (Dorig et al., 1993; Gerlier 
et al., 1994), which is expressed on all human nucleated 
cells, for entry (Navaratnarajah et al., 2009). After 
infection, MV induces morphological changes of the 
cell layer, a so called Cytopathic Effect (CPE) in 
infected cell cultures. MV infection is accompanied by 
cell-to-cell fusion and formation of multi-nucleated 
giant cells, so called syncytia (Fig. 1C). In the late 
stages of MV infection, apoptosis and the lysis of the 
cells are induced. During the amplification phase, a 
considerable part of the MV particles remains cell-
associated, while some particles are released from the 
cell membrane via budding (Morgan and Rapp, 1977). 
1.1. Application of Attenuated Measles Virus 
 The initial isolation of the MV was done by Enders 
and Peebles (1954). The isolated strain has been derived 
from the throat washings of an 11 years old measles 
patient named David Edmonston and was therefore 
named Edmonston strain (Enders and Peebles, 1954). 
This measles virus strain was adapted to cell culture and 
attenuated by serial tissue culture passages resulting in 
less virulent virus strains, e.g., Edmonston B. Thus, this 
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isolate has become the progenitor for many attenuated 
strains which are currently in the use for vaccination, 
(Fig. 2A) or research investigation. 
1.2. Use of Measles Virus For Vaccination  
 It was Thomas Peebles who obtained specimens 
from a measles outbreak in 1954. Meanwhile, human 
kidney cells had been successfully cultured in vitro in the 
Enders lab. 
 In these cells, MV could be successfully cultivated 
for the first time and has been subsequently passaged 23 
times. After inoculation of these passaged virus particles 
in measles-susceptible monkeys (cynomolgus monkeys), 
the animals developed fever, rash, viremia and anti-MV 
antibodies (Peebles et al., 1957). After one further 
passage, the cultured MV had been transferred to human 
amnion cell cultures and then to chicken eggs for 28 and 
6 passages, respectively (Milovanovic et al., 1957). 
Afterwards, the virus was passaged in chicken embryo 
fibroblasts for 13 times. When the virus particles were 
then inoculated into measles-susceptible monkeys, no 
disease symptoms, but complement-fixing and 
neutralizing-antibodies were observed (Katz et al., 1958; 
Enders et al., 1960). These monkeys were than resistant 
to infection with “wild type”, pathogenic MV. Based on 
these results a vaccine strain was developed and licensed 
in 1963 (Katz, 2009). Thus, measles vaccination became 
possible that enables control of measles epidemics. 
 Today, several MV strains are used and licensed for 
vaccination, e.g., the Moraten Vaccine (Merck) (Scheld 
et al., 2004) or AIK-C, Schwarz F88, CAM-70 and 
TD97, (Fig. 2B) (Artenstein, 2009). These vaccines have 
been used in millions of doses and have revealed an 
excellent safety profile. 
 Measles vaccine is currently produced by standard 
cell culture techniques in chicken embryo fibroblasts 
(Bronzino, 2000). The used process systems are mainly 
roller bottles or multilayer stacked plate systems (cell 
factories). Compared to petri dishes or T-flasks, a larger 
surface can be obtained with these systems.  
1.3. Potential of Measles Virus for Cancer Therapy 
 Apart from vaccination, attenuated MV has a natural 
ability to specifically kill cancer cells. Attenuated MV 
enters the cell via the receptor CD46, which is frequently 
over-expressed on tumor cells (Davis and Fang, 2005). 
As MV is a lytic virus, MV replication in tumor cells 
leads to cell lysis of cancer cells. Intratumoral injection 
of the unmodified MV Edmonston strain or an 
Edmonston strain derived recombinant MV induced 
regression of large established human lymphoma 
xenografts in murine models (Grote et al., 2001). This 
oncolytic virus has also been reported to have potency 
against human epithelial ovarian cancer cells in vitro and 
in vivo, being selectively lytic for the ovarian tumor cells 
(Peng et al., 2002), hepatocellular carcinoma (Blechacz 
et al., 2006), or prostate cancer cells (Msaouel et al., 
2009b), among others. Russell et al. (2010) filed a patent 
application which describes a method for limiting the 
growth of cancer cells using an attenuated MV strain. 
This oncolytic property qualifies MV for cancer therapy 
approaches and is currently examined in clinical trials 
with human cancer patients (Davis and Fang, 2005). 
Furthermore, new oncolytic MVs have been created as 
next generation therapeutics, which specifically target 
the cancer cells (Nakamura et al., 2005; Springfeld et al., 
2006; Hasegawa et al., 2007; Mühlebach et al., 2010; 
Leber et al., 2011). 
 One problem of using oncolytic measles viruses for 
cancer treatment is the sheer amount of virus needed. 
Similar to virus particle based gene therapy (Nehring et 
al., 2004; 2006; 2009) the measles virus quantity for a 
therapeutic dose is three to 6 log10 units higher than for 
vaccination (Msaouel et al., 2009a; 2011; Davis and 
Fang, 2005; Russell et al., 2010). Searching for a 
production process for oncolytic virus particles the 
question arises, whether the production process for 
MV vaccines cannot simply be expanded. To answer 
this question, the specific requirements for MV 
production are discussed in this review. 
1.4. Oncolytic MV Particles: New Aspects for 
MV Production 
 Currently, there is just one detailed description for 
MV production in larger scales (60 L) for oncolytic 
therapy available, where a detailed protocol for the 
purification and the serum-free production with Vero 
cells in cell factories is presented (Langfield et al., 
2011). Measles vaccines are routinely still produced 
using chicken embryo fibroblasts and standard cell 
culture techniques. While this process works for that 
specific purpose, it is not easily transferable for oncolytic 
virotherapy applications due to the up to 6 log10 units 
higher amounts of virus needed. Therefore, a massive 
scale up of the production process is required. All 
currently industrial used processes for measles 
vaccine production are monolayer cultures with non-
uniform cell growth, limiting oxygen transport and 
inhomogeneous nutrient supply. From the bioprocess 
point of view, these processes are neither controllable, 
nor do they yield standardized and reproducible virus 
qualities and quantities.  
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Fig. 2. Histories of Edmonston derived (A) and non-Edmonston (B) derived vaccines (obtained from (Bankamp et al., 2011), with 
permission). Derived strains are indicated by the abbreviation of the cell culture used and the number of passages performed. 
The temperature was assumed to be 37°C, other used temperatures were indicated by numbers in brackets. 
CAM…chorioallantoic cavity of chick embryo; CE(am)…intraamniotic cavity of chick embryo; CEF…chick embryo 
fibroblast; DK…dog kidney; HA…human amnion; HK…human kidney; SK…sheep kidney; WI-38…human diploid cells; 
*Plaque purification. 
 
 Furthermore, an efficient scale up of these processes is 
difficult and requires expensive robotic automations 
(Bronzino, 2000; Trabelsi et al., 2010). To expand these 
existing systems in a way that over 1 million times higher 
numbers of infectious particles per dose are produced, 
would be, even if possible, very inefficient.  
 Another point to consider is the virus per se, 
especially for those oncolytic virus particles that are fully 
retargeted for cancer cells. For the latter, the virus 
recognizes only receptors expressed on human cancer 
cells and propagation of these oncolytic viruses in chicken 
embryo cells will therefore not be possible. Thus, at least 
some oncolytic MV viruses have to be produced in special 
cells developed for this purpose, e.g. Vero-HIS cells 
(Nakamura et al., 2005). For these special cells, a new 
process has to be established, anyway. Fermentation 
techniques enable high efficient production of very large 
volumes to provide the necessary quantity of the desired 
product. Production processes in bioreactors reduce 
overall costs and shortens time. This can easily be 
presented by evaluating the productivity (space-time 
yield), which describes the ratio of the amount of desired 
product, that is generated and the time and volume needed 
for this purpose. The productivity of conventional 
cultivation systems (e.g., cell factories) compared to 
bioreactors is supposed to be lower.  
 Scaling up in a bioreactor requires an increase in the 
reactor vessel while the operating effort stays the same. 
In contrast a scale up in a cell factory production process 
means increasing the number of cell factories. These 
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additional cell factories have to be handled, which increases 
required material, staff costs and handling time.  
 Besides, bioreactor systems are characterized by its 
complex design and high level of instrumentation which 
enables online measurement and in process control with 
reproducibility efforts and GMP standardization. In 
Table 1 the main advantages and disadvantages of the 
two systems are compared. 
 The purpose of this review is to summarize 
published production processes for MV and factors 
influencing the virus yield. Moreover, it indicates 
starting points for further analysis to obtain sufficient 
amount of virus particles for oncolytic therapy. Other 
aspects of MV virotherapy have been reviewed already 
and for this reason were not covered in this review. Details 
covering MV biology are summarized in (Griffin and 
Oldstone, 2008), the current state of oncolytic trials with 
measles viruses is described by (Msaouel et al., 2009a, 
Msaouel et al., 2011). Additionally, Langfield et al. 
(2011) and Udem (1984) provide detailed description of 
methods for MV purification. 
1.5. Measles Virus Production 
 Starting with the demonstration that MV could be 
propagated in human and simian cell cultures (Enders 
and Peebles, 1954), a considerable amount of data has 
been published on MV production. MV amplification 
has been described in various cell lines and with 
various culture modes. Parameters such as virus 
stability, composition of medium and virus amount 
have already been analyzed. Concerning an 
optimization of the production process, only few data 
have been published. The outcome in the published 
data was evaluated by the cell-associated and 
extracellular virus titers. For MV, two main methods 
evaluating titers of infectious MV are used. For 
infectivity titration, virus suspensions are diluted and 
endpoint dilutions are determined, at which infection is 
detectable (often by the appearance of syncytia) (Reed 
and Muench, 1938). Using statistics, virus titers are 
subsequently calculated as Tissue Culture Infective 
Dose (TCID50) (Kärber, 1931), which indicates the 
dilution of the respective virus particle suspension, at 
which infection is detectable in 50% of inoculated 
cultures. Another option of virus quantification is the 
evaluation of plaque formation. Employing this 
method, cells are infected with various virus dilutions 
and after an adsorption period of about two hours, a 
soft agar overlay containing all medium compositions 
is added (Mayer, 1960; Rapp, 1964). Due to the 
spread of the virus via cell lysis, areas of virus-
induced cell destruction appear as so called plaques. 
The number of plaques is then counted after a defined 
period of time. According to this method the virus 
titers are given in plaque forming units (pfu). Thus, 
the pfu method describes an infectivity that is directly 
quantified, whereas the TCID50 is a statistical 
description of a probability of infection with 50% 
chance. Accordingly, a titer of 1×105 TCID50 mL−1 
corresponds to approximately 0.7×105 pfu mL−1. 
 In the following, measles virus has been produced 
using serum supplemented medium, if not specified 
otherwise. 
1.6. Impact of Virus Strain and Cell Type for 
Measles Virus Production 
 MV production has been analysed in several cell 
types and with several virus strains. Matumoto (1966) 
gives an overview of various cell lines, which had been 
analysed and could be usefull for MV production. While 
research groups have determined various cell types for 
their susceptibility to MV, industrial MV production 
(vaccines) are still routinely produced using chicken 
embryo cells (Bronzino, 2000). 
 
Table 1. Comparison of conventional (e.g., cell factories) and bioreactor system for cell culture cultivation and production. 
Presentation of the main advantages and disadvantages of the respective system 
Conventional cultivation (e.g., cell factories) bioreactor cultivation 
Simple design Often more complex design 
Low level of instrumentation, but requires transport Requires external equipment (e.g., heating  
of the whole culture to e.g., work bench for medium circuit, sterile couplers) 
exchange 
Low level of control (limitation of metabolites) Possibility of direct regulation for appropriate
 physical and chemical requirements 
Due to static cultivation development of local Increased homogeneity 
concentration gradients 
Due to increased inhomogeneity reduced Increased stability and reproducibility 
stability and reproducibility 
Ease of handling in small scale Easier to handle in larger scales 
During cultivation measurement of parameters Online monitoring of process parameters with  
hard to perform integrated sensor 
Insufficient oxygen supply for high cell densities Increased oxygen transfer into the medium
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1.7. The Edmonston Strain 
 As already mentioned, the Edmonston strain is up to 
now the most commonly used strain for vaccine 
development. The maximum virus yield obtained with the 
Edmonston strain has been determined by different 
groups, while various cell lines were infected with this 
MV strain (Black, 1959; Kohn and Yassky, 1962; Nakai et 
al., 1969; Romano and Scarlata, 1973; Baczko and 
Lazzarini, 1979; Brandriss et al., 1982; Scott and 
Choppin, 1982; Mendonca et al., 1994; 2002) (Table 2). 
 Black (1959) gained a maximum titer of 6.3×105 
pfu mL−1 with Hep-2 cells, whereas Romano and 
Scarlata (1973) described a maximum titer of 4.6×104 
TCID50 mL−1 in HeLa cells and Udem (1984) a 
maximum of 1×108 pfu/mL in HeLa cells. In KB cells, 
a maximum titer of 5.6×106 TCID50 mL−1 was 
obtained (Kohn and Yassky, 1962). A maximum value 
of 1×107 pfu mL−1 was produced with BSC-1 cells 
(Nakai et al., 1969), whereas MV produced in Vero 
cells had a maximum titer of 1.7×108 TCID50 mL−1 
(Mendonca et al., 1994; 2002). MV production in the 
suspension cell line U937 resulted in a titer of 
6×106 pfu mL−1 (Brandriss et al., 1982). A comparison 
of Vero, BGMK, CV-1, Hep-2, AV3, BHK-21, PK-15 
and MDCK cells infected with the Edmonston strain 
revealed that Vero and BGMK cells produced the 
highest virus yields (Scott and Choppin, 1982). The 
yield with Vero cells was slightly higher with a maximum 
value of 2.8×108 pfu mL−1. Other cell lines had reduced 
virus production, with 7-28,000 times lower titres. MDCK 
cells had the lowest production rate with just 1×104 
pfu mL−1 (Scott and Choppin, 1982).  
 A further analysis of MV production in Vero and 
MA160 cell monolayers as well as MA160 cells cultured 
in suspension has been published. A maximum titer of 
approx. 30 pfu per cell was described on MA160 
monolayers, while the titers in Vero cells were 
approximately three times lower. In contrast, with 
suspension culture of MA160 cells, a yield of 100-800 pfu 
per cell (equals 2×107-1.6×108 pfu mL−1) could be 
reached; this is an increase of 20-100 times compared to 
the monolayer titers. However, besides the parameters cell 
types and culture mode, the medium supplements have 
also been varied during the three culture set-ups (Baczko 
and Lazzarini, 1979). Thus, no absolute comparison is 
feasible, since the impact of medium composition on MV 
production yields has already been documented, as well 
(Romano and Scarlata, 1973; Scott and Choppin, 1982). 
Taken together, these data maybe helpful for choosing an 
optimal MV producer cell line, but have to be interpreted 
with respect to the composition of the medium. 
1.8. Other Measles Virus Strains 
 Besides the Edmonston lineage, several other strains 
of MV have also been examined. These are the Hallé 
strain (Dubois-Dalcq and Reese, 1975; Scott and 
Choppin, 1982), the TYCSA strain (a variant of the 
Toyoshima strain) (Shishido et al., 1967), the Leningrad-
16 strain (Boriskin et al., 1988; Sidorenko et al., 1989) 
and the AIK-C strain (Trabelsi et al., 2010) (Table 2). 
 Production of the Hallé strain in Vero cells was 
characterized by electron microscopy. Due to these data 
it has been suggested that infected Vero cells do not 
complete the first cycle of viral replication within 24 h 
after infection. At this time point, cell fusion was just 
starting; neither budding nor complete virus particles 
could be observed. In contrast, the whole monolayer 
appeared to be covered with syncytia after three days and 
viral budding could be illustrated (Dubois-Dalcq and 
Reese, 1975). These observations are in agreement with 
previous data published for MV growth curves for the 
Edmonston strain in other cell lines (Black, 1959; Nakai 
et al., 1969). 
 Scott and Choppin (1982) compared the virus 
production between the Edmonston and the Hallé strains. 
Infection with the Edmonston strain resulted in slightly 
higher maximum MV yields compared to Hallé 
(approximately 1×108 vs. 2.5×108 pfu mL−1, respectively).  
 Vero cells infected with the TYCSA strain produced a 
maximum titer of 3×106 TCID50 mL−1 (Shishido et al., 
1967), whereas the Leningrad-16 strain amplified in quail 
embryo cells (Boriskin et al., 1988; Sidorenko et al., 
1989), resulted in maximum titers of 1×107 or 3.6×105 
TCID50 mL−1 (Boriskin et al., 1988). Finally, infection of 
MRC-5 cells with the AIK-C strain resulted in a 
maximum titer of 1×1011 TCID50 mL−1 (Trabelsi et al., 
2010). This is to our knowledge the highest titer, which 
has been reported for MV, yet. Table 2 summarizes 
maximum titers as discussed above. Direct comparison 
of various cell lines and measles virus strains has only 
been performed by (Scott and Choppin, 1982), so far, 
who documented the highest yields using Vero cells 
and the Edmonston strain. As other publications 
though reported higher yields with other cells and 
strains, the comparability of the data from different 
publications is not necessarily given. Especially for 
individual uses such as recombinant retargeted viruses 
for cancer therapy, investigations have to be 
performed with this strain anyway. 
1.9. Stability of Measles Virus 
 Several parameters can influence the stability of MV 
particles. While some factors such as temperature or pH 
may inactivate the virus, others like certain salt supplements 
are able to stabilize the infectivity of the virus.  
Weiss, K. et al. / American Journal of Biochemistry and Biotechnology 8 (2) (2012) 81-98 
87 Science Publications
 
AJBB 
Table 2. Cell type and MV strain for MV production. Summary of the main virus strains which were produced with different cell 
lines. For better comparability, titers in pfu were converted in TCID50 by multiplication with the factor 0.7 
  max. titer (×106 
MV strain Cell line TCID50/mL) Ref. 
Edmonston AV3 2.800 (Scott and Choppin, 1982) 
 BGMK 154.000 (Scott and Choppin, 1982) 
 BHK-21 0.014 (Scott and Choppin, 1982) 
 BSC-1 14.000 (Nakai et al., 1969) 
 CV-1 28.000 (Scott and Choppin, 1982) 
 HeLa 0.046 (Romano and Scarlata, 1973) 
  70.000 (Udem, 1984) 
 Hep-2 8.400 (Scott and Choppin, 1982) 
  0.630 (Black, 1959) 
 KB 0.560 (Kohn and Yassky, 1962) 
 MA160 230.000 (Baczko and Lazzarini, 1979) 
 MDCK 0.007 (Scott and Choppin, 1982) 
 PK-15 0.007 (Scott and Choppin, 1982) 
 U937 8.600 (Brandriss et al., 1982) 
 Vero 196.000 (Scott and Choppin, 1982) 
  170.000 (Mendonca et al., 1994) 
  8.000 (Mendonca et al., 2002) 
AIK-C MRC-5 100,000.000 (Trabelsi et al., 2010) 
  10.000 (Trabelsi et al., 2012) 
Leningrad-16 strain quail embryo cells 10.000 (Boriskin et al., 1988) 
  0.360 (Sidorenko et al., 1989) 
TYCSA Vero 3.000 (Shishido et al., 1967) 
Halle  70.000 (Scott and Choppin, 1982) 
 
 
Fig. 3. Residual infectivity of measles virus at various pH. MV 
was mixed with two volumes of cold buffer solutions of 
various pH values and incubated for 3 h in an ice bath. 
Determination of the virus titer was evaluated by 
titration (plaque method). Infectivity was normalized to 
optimal pH 7.6 and residual infectivity is plotted against 
pH. Figure is based on data published by Black (1959). 
Temperature dependent inactivation of MV at 37°C has 
been reported to proceed at a rate of about 0.15 log10 
units per hour, which represents a viral half-life of 
about two hours (Black, 1959). Kohn and Yassky 
(1962) also reported a high inactivation rate of MV at 
37°C, with a drop in infectivity by 90% in 16 h or 
1.4 log10 units per 24 h. Due to MV´s high susceptibility 
to temperature-inactivation (Black, 1959; Kohn and 
Yassky, 1962), there has been considerable interest in 
stabilizing the virus. Rapp et al. (1965) reported the 
impact of various salt solutions on the stability of MV. 
Dilutions of infectious particle preparations in 1 M MgSO4 
and 1 M Na2SO4 stabilized the virus. In contrast, in other 
salt solutions (CaCl2, NaCl, KCl, K2SO4 and Na2HPO4), or 
in pure water, a decrease of one to more than three log10 
units was observed within 15 min at 50°C. With MgSO4 
and Na2SO4, only slight decreases of 0.2 or 0.4 log10 units, 
respectively, were observed. Furthermore, MV 
inactivation at 50°C decreased with increasing MgSO4 
concentration. However, an increasing concentration of 
MgCl2 enhanced the inactivation of MV. These results 
indicate that sulfate ions may protect MV against thermal 
inactivation (Rapp et al., 1965). 
 Boriskin et al. (1988) analyzed the impact of MgSO4 
on MV yields, again (Boriskin et al., 1988). Here, the 
same thermal inactivation rate of MV in the absence and 
presence of MgSO4 was observed. It has been suggested 
that sulfate ions cannot protect the virus from heat 
inactivation in contrast to the previously cited publication 
(Rapp et al., 1965). As an explanation for this 
discrepancy, the addition of MgSO4 to the culture 
medium was described to result in earlier plaque 
formation and thus in an increase of apparent titers by up 
to 200-fold. MgCl2 supplementation showed no 
stimulating effect and the addition of Na2SO4 showed a 
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maximum virus increase of apparent titer of only 10-fold 
(Boriskin et al., 1988). Thus, certain ions may increase 
virus production or infectivity, but not its stability. This 
was further documented by analyzing MV NP protein 
synthesis by radioimmune precipitation and SDS-
PAGE, where MV ribonucleocapsid protein appears in 
untreated cells to a much lesser extent, as compared to 
MgSO4 treated cells (Boriskin et al., 1988). 
 The pH sensitivity of MV has also been analyzed. 
Figure 3 presents residual infectivity of MV at various 
pH (Black, 1959) showing a highest stability at pH 7.6 
and a progressive inactivation of MV for both 
acidification and alkalinization results. 
 MV particles are highly susceptible to temperature 
and pH dependent inactivation (Black, 1959; Kohn and 
Yassky, 1962; Rapp et al., 1965; Boriskin et al., 1988). 
Therefore it can be concluded, that during production 
released virus is inactivated very fast in the supernatant. 
For maximum virus yields, immediate cooling after the 
harvest, repeated harvesting in at least hourly intervals, 
further additional analyses for stabilizing the virus 
particles and online measurements and regulation of the 
pH during MV production are thus required.  
1.10. Extracellular and Cell-Associated Virus 
 While production of MV components is inside the 
infected cell, all parts accumulate at the cell membrane 
and are released via budding. These active and complete 
MV particles appear extracellular. Other particles stay 
cell-associated. In the last phase of virus replication 
infectious virus as well as non-infectious virus 
components and particles can be released through cell 
disruption. 
 The derivation of the virus preparation is important, 
since extracellular virus is better to handle, as it is easy to 
separate from cells. Intracellular virus particles require 
cell disruption, thereby releasing potential impurities, i.e., 
cellular and viral components besides infectious particles, 
into the preparation.  
 One of the first reports about MV production in Hep-
2 cells examined extracellular and cell-associated MV 
concentration during infection (Black, 1959). Although 
the cell disruption method, a one-step freeze-thaw cycle 
at -5°C, was referred to as incomplete, the amounts of 
extracellular virus were always lower than cell-associated 
yields. Infectious cell-associated virus had been found 
first after 15-18 h p.i. and extracellular virus could be 
observed about 26 h post infection. For both, maximum 
virus titers appeared after 48 h p.i. While cell-associated 
virus titers decreased after 48 h p.i. the yields for 
extracellular virus remained constant suggesting 
continuous virus release. This was confirmed by thermal-
stability studies, as well. As previously mentioned, MV 
has a half-life of 2 h at 37°C (Black, 1959). Extracellular 
virus titer could remain constant, because there seems to 
be equilibrium between virus release and decay.  
 In another study by Nakai et al. (1969) the yields of 
released virus and cell-associated virus were always 
within the same range (maximum titers of approximately 
5×106 pfu mL−1). Higher extracellular yields appeared 
with increasing cell-associated virus titers, also 
suggesting a continuous budding of virus particles (Nakai 
et al., 1969). Interestingly, HeLa cells showed 
temperature dependant virus release. While at 37°C 
between a maximum of ~ 80 and 98% of the virus 
particles remained cell-associated, at 32.5°C more than 
50% of the virus had been released not later than 60 h p.i. 
(Udem, 1984). 
 Shishido et al. (1967) infected Vero cells with a 
variant of the Toyoshima strain; MV titers started to 
increase for cell-associated virus about 12 h after 
infection, for extracellular virus about 18 h p.i. Titers 
decreased after 72 h p.i. for both, extracellular and cell-
associated, virus populations. Maximum yields were 
about 3×106 for cell-associated and 5×105 TCID50 mL−1 
for released virus. Except for the end of the cultivation 
period, cell-associated virus titers were always one to two 
log10 units higher than extracellular titers (Shishido et al., 
1967). Accordingly, released virus in Vero and MA160 
cells infected with the Edmonston strain represented only 
about 10% of the total amount of infectious virus 
(Baczko and Lazzarini, 1979). However, concentrations 
of cell-associated and extracellular virus were similar for 
BSC-1 cells infected with a virulent Edmonston 
derivative of MV, whereas attenuated virus remained to 
more than 95% cell-associated (Rapp, 1964). 
 These experiments were all performed in static 
systems, e.g., petri dishes. In bioreactor cultivation with 
Vero  cells,  the  extracellular  yield  for  MV  of  the 
Edmonston  strain  was  lower  than  intracellular virus 
titer,  as  well.  While  the  extracellular  TCID50  per  mL 
was  reduced  by  the  value  of  about 1.1 log10, the total 
virus titer was only lowered by 0.4 log10 (Mendonca et 
al., 1994).  
 Using the suspension cell line U937 in spinner 
system, less than 20% of the total amount appeared 
extracellular in spinner flasks (Brandriss et al., 1982), 
whereas during production with the suspension cell line 
MA160 in spinner flasks about 10% of the total virus had 
been released (Baczko and Lazzarini, 1979).  
 Finally, the titers of cell-associated virus have almost 
always been reported to be higher than extracellular 
titers. Yields of cell-associated virus were mainly within 
a range of 50% up to 98% of total virus titers. 
Nevertheless, as already mentioned, serial harvesting of 
released virus should be considered. Since cell-associated 
virus can be harvested only once, cumulative titers of 
extracellular virus could exceed cell-associated yields. 
1.11. Impact of Medium Composition on Measles 
Virus Production  
 In general, the medium composition has a great 
impact on the outcome of a production process. There are 
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several components and supplements necessary or 
advantageous for cell cultivation and therefore virus 
production. Since the special requirements of infected 
cells are unknown, there is considerable need for detailed 
studies concerning these factors. 
1.12. Impact of Serum  
 Serum, mostly Fetal Calf Serum (FCS), is generally 
supplemented to cell culture media as it provides growth 
factors, vitamins, hormones, amino acids, substances for 
adhesion and cytokines. It is supplemented for cell 
culture usually in amounts varying between 
3 and 25% (v/v). Serum as a preparation of primary 
material is not completely characterized, but often 
essential. The use of serum-free fully defined media is 
often preferred for more robust and reproducible 
processes especially for the production of therapeutics.  
 The impact of serum content on MV production was 
analyzed by producing the Edmonston strain of MV on 
Vero cells in the absence and presence of 10% FCS. 
Titers (pfu per mL) were 0.5-1.5 log10 units higher with 
10% FCS than without (48 pfu per cell). With increasing 
FCS concentration (no serum, 2% and 10%) the virus 
yield increased. Substitution with calf or horse serum 
resulted in similar effects, although the use of FCS 
resulted in slightly higher titers. The addition of 10 mM 
HEPES to FCS (10%) supplemented medium resulted in 
a titer of 185 pfu per cell. Cultivation of infected cells 
without FCS, but with just 10 mM HEPES or just 
5 µg mL−1 insulin resulted in a virus titer of 
65 or 123 pfu per cell, respectively, while the highest 
amount (191 pfu per cell) was obtained using all 
supplements (10% FCS, HEPES and insulin) (Scott and 
Choppin, 1982).  
 Using M199 Medium after infection with different 
supplements (none, 2% FCS, 0.2% gelatin, or 0.5% BSA) 
resulted in quite similar titers. The highest titer had been 
reached with BSA supplemented medium 
(107 TCID50 mL−1). The lowest titer was equal to 3.2×106 
 TCID50 mL−1 and resulted with M199 medium without 
any supplements (Trabelsi et al., 2012). 
1.13. Impact of Amino Acids in the Culture 
Medium 
 Most cell lines depend on supplemented amino 
acids to maintain their metabolism during in vitro 
cultivation. Two media have been compared with 
respect to microscopically detectable morphological 
changes of infected Hep-2 cells (Reissig et al., 1956). 
Enders medium contained bovine amniotic fluid, beef 
embryo extract, heated horse serum and Hanks balanced 
salt solution. Eagles (1955) medium was supplemented 
with amino acids and serous enrichments as described 
and has been additionally supplemented with calf 
serum. Up to tenfold higher virus yields were observed 
in Eagles medium compared to Enders medium (exact 
values had not been published). Additionally, the 
morphology of the cellular monolayer was different. In 
Enders medium, the monolayer was transformed into 
few large syncytia. In Eagles medium, the cells 
appeared more as a network and became rounded in 
shape (Fig. 4) (Reissig et al., 1956). 
 When Enders medium was additionally 
supplemented with glutamine, the morphology of the cell 
sheet was similar to that in Eagles medium. The other 
way around, using glutamine deficient Eagle’s medium, 
the cell morphology corresponds to the morphology of 
the cells in the normal Enders medium. This result suggests 
that the morphological changes were due to glutamine 
omission. Hence, the authors concluded, that the presence or 
absence of glutamine in the medium was the reason for the 
different virus titer (Reissig et al., 1956). 
 The amino acid requirements for MV production 
have been examined in HeLa cells, as well (Romano and 
Scarlata, 1973). For that purpose, the omission or 
addition of certain amino acids (tryptophan, cysteine, 
tyrosine, leucine, valine, phenylalanine, isoleucine, 
threonine, methionine, lysine, histidine, glutamine and 
arginine) was analyzed by comparing plaque formation 
in the infected cells. The respective amino acids were 
additionally supplemented to a final concentration of 
0.5 mM to Eagle’s Basal Medium (EBM) without serum. 
The results were normalized to titers produced in EBM 
supplemented with all amino acids and set as 100%. The 
production of MV in this reference medium reached 4.6×104 
TCID50 mL−1 (Romano and Scarlata, 1973). 
 Three amino acids (arginine, methionine and 
glutamine) exerted major impact on the number of 
plaques and on virus production. The omission of these 
three amino acids always reduced MV yields, but the 
additional supplementation of arginine and glutamine to 
the higher concentrations of 0.5 mM, resulted in 
increased viral titers. In EBM without arginine, plaque 
formation was reduced to only 15%. An increase of 
arginine concentration up to 0.5 mM resulted in 2 fold 
higher plaque formation. The virus production in 
arginine-deprived medium resulted in a maximum titer of 
only 21 TCID50 mL−1 48 h p.i. thus three log10 units lower 
as compared to the reference. Methionine seems to be an 
essential amino acid for the production of MV in HeLa 
cells, as well. The absence of methionine resulted in early 
cell death, even before plaque formation became evident. 
For virus production without methionine, the titers did 
not exceed 32 TCID50 mL−1. The increase of methionine 
up to 0.5 mM did not increase maximum plaque 
formation above reference. However, addition of 0.5 mM 
methionine to cells with preceding methionine omission 
resulted in a three log10 units-fold increase of the virus 
titer (up to 3.2×103 TCID50 mL−1) within the next 10 h. 
The third essential amino acid, glutamine, had similar 
effects as methionine. MV infection in the absence of 
glutamine was accompanied by early cell death without 
plaque formation. On the contrary, a glutamine 
concentration of 0.5 mM in the medium caused an 
increase of plaque formation to 1.5-fold higher numbers 
than the reference (Romano and Scarlata, 1973). 
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Fig. 4. Morphology of MV-infected Hep-2 cells cultured in different media (obtained from (Reissig et al., 1956), with permission). 
Hep-2 cells grown in (A) Enders medium supplemented with bovine amniotic fluid, beef embryo extract, heated horse serum 
and Hanks balanced salt solution or (B) Eagles medium supplemented with amino acids and serous enrichments and calf 
serum. Cells were infected with the Edmonston strain of MV. Depicted are infected monolayer cultures ten days p.i. Phase 
contrast, about 60 x magnification. 
 Other amino acids had no or a negative impact on 
MV replication and production. Tryptophan deprivation 
had no influence on plaque formation, while the addition 
of 0.5 mM of tryptophan was cytotoxic, resulting in 
rounded-up cells and a 50% decrease in plaque 
formation. The deprivation of isoleucine and threonine 
caused only 35% plaque formation and virus titers 
reached a maximum of 3.2×103 and 1×103 TCID50 mL−1 
48 h p.i. respectively. The omission of the other amino 
acids resulted in 65-90% plaque formation, except for the 
deprivation of lysine, which revealed unchanged plaque 
formation. Increased concentrations of other amino acids 
had no influence on plaque formation. The highest MV 
titer (1×104 TCID50 mL−1), apart from the reference, was 
reached after 48 h p.i. in culture medium without 
tryptophan, lysine, cysteine and glutamine (Romano and 
Scarlata, 1973). 
 While reduced titers have been reported by the 
omission of serum, some components in serum seem to 
be essential for MV production. As serum is complex and 
chemically undefined process instability and problems 
with batch to batch reproducibility are to be expected. 
Analyzing the available data, the amino acids arginine, 
methionine and glutamine seem to be important for high 
titers. However, this may vary with cell line and virus 
strain. In general, there are too little data available for 
robust interpretation. The special requirements 
considering amino acids of the host cells are still 
unknown, although glutamine has often been reported to 
be essential for MV production. Kinetic studies should be 
performed ideally with fully defined synthetic medium, 
which then enables implementation of optimal nutrient 
supply for MV production.  
1.14. Impact of Multiplicity of Infection (MOI) on 
Measles Virus Production 
 The MOI describes the ratio of infectious agent 
(here: MV) to the infection target (cells). In general, MV 
infection for production purposes is performed at low 
MOI’s around 0.02 (Kohn and Yassky, 1962; Brandriss 
et al., 1982; Boriskin et al., 1988, Sidorenko et al., 1989; 
Trabelsi et al., 2010). 
 Nakai et al. (1969) studied MV production by 
electron microscopy and varied the MOI. Bundles of 
filaments with a tubular nature, called tubules, were 
observed in infected cells´ cytoplasm. These tubules were 
associated with the budding process. With ongoing MV 
replication, the tubules became larger and more 
numerous. Therefore, these tubules might be interpreted 
as MV nucleoprotein aggregates. Additionally, these 
tubules appeared in the nucleus, as well. These nuclear 
tubules were observed, when the cells were infected with 
an MOI of 10. They appeared 24 h p.i. but they remained 
very sparse and poorly developed. The resulting 
extracellular virus titer was 104 pfu mL−1 and no budding 
particles could be detected at any time. With lower MOI, 
the appearance of well-developed cytoplasmic tubules 
was observed 18 h p.i., extensive budding activity was 
evident after 30 h p.i. The titer of extracellular virus was 
three log10 units higher (107 pfu mL−1) than the one 
observed with an MOI of 10 (Nakai et al., 1969).  
 Preferentially low MOI for producing high-titer MV 
was also demonstrated for BSC-1 cells. With an MOI of 
1, the titers increased until day 2 p.i. and then remained 
stable. The highest values were about 1×106 and 
2×105 pfu mL−1 for cell-associated or extracellular virus, 
respectively. With a lower MOI of 0.01, the MV titers 
increased until day 3 and reached a maximum titer of 
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5×106 pfu cell-1 for both cell-associated and extracellular 
virus (Nakai et al., 1969). 
 For the production in Vero cell monolayers, the 
impact of MOI was analyzed by increasing the MOI in 
log10 steps from 0.001-10 (Scott and Choppin, 1982). All 
maximum virus titers were between 107 and 
108 pfu mL−1. However, the highest MOI gave rise to the 
lowest maximum titer. In contrast, the best virus yield 
was produced with an MOI of 0.01, but reduction of the 
MOI elongated the time of virus production by about 5 
days (Scott and Choppin, 1982). 
 In another study, the overall yield of MV production 
in Vero cell monolayers was higher with an MOI of 0.1 
compared to an MOI of 10. However, using an MOI of 
10, viral titers were higher until 48 h p.i. but production 
had to be terminated earlier (72 h MOI 10 vs. 96 h MOI 
0.1) (Baczko and Lazzarini, 1979). In the same report, 
the titers in MA160 cell monolayers after infection with 
an MOI of 10 were always higher than titers reported 
after infection with MOI of 0.1. Again, using an MOI of 
10, virus production had to be terminated one day earlier 
(96 h p.i. Vs 120 h p.i. respectively). In contrast, in 
MA160 suspension culture, the MV titer with MOI 10 
were higher until 48 h p.i. while better titers appeared 
with an MOI of 0.1 starting 72 h p.i. until the end 
(Baczko and Lazzarini, 1979). 
 In MRC-5 cells the influence of the MOI was 
studied, too. The MOI was varied in steps of 0.01, 
0.005 and 0.001. The highest titer was observed with 
an MOI of 0.01 (7.5×106 TCID50 mL−1), although the 
titers with an MOI of 0.005 and 0.001 were only 
slightly lower (1.8×106 and 7.5×105 TCID50 mL−1) 
(Trabelsi et al., 2012). 
 In contrast to the results discussed above, with HeLa 
cells the more virus particles was produced the higher the 
MOI (0.01, 0.1 and 1) was. Interestingly, the maximum 
virus titer increased with increasing MOI to a more 
drastic rate at 37°C (up to three log10 units) than it did at 
32.5°C (up to one log10 unit) (Udem, 1984). 
 In most cases, a lower MOI was reported to be 
associated with higher viral titers. However, high MOI 
shortens production time, but increases the amount of virus 
needed for infection. Since economical consideration play 
a significant role in optimizing production processes, it 
should be noted that longer cultivation times and increased 
amounts for infection (higher MOI) cause higher 
production costs. On the other hand, with serial virus 
harvests as suggested above, the longer the time of 
production, the higher is the total generated virus amount. 
Thus, total yields with low MOI and serial virus harvests 
could be beneficial over longer production time in terms of 
production costs. 
1.15. Impact of Culture Systems for Measles 
Virus Production  
 As already described for monolayer and suspension 
cultures, the choice of the culture system exerts 
considerable impact on virus production and the 
scalability of a process. Potential culture systems for MV 
production are in the range from small, simple and 
uncontrolled systems such as monolayer cultivation in T-
flask or petri dishes up to highly controlled cultivation 
systems in large scales (e.g., Stirred Tank Reactors 
(STR)). Current MV vaccine production is performed 
mainly in adherent cells. As adherent cell lines usually 
need a growth surface to attach, the cultivation in a 
suspension culture such as in bioreactors can be 
supported by so called microcarriers. These 
microcarriers, on which the cells can grow, are small 
round or flat particles, which can easily be suspended 
by a stirrer. 
1.16. Spinner Flask Cultivation  
 Boriskin et al. (1988) first reported MV production 
with cells cultivated on microcarriers. Quail embryo 
fibroblasts were cultivated on Cytolar-2 microcarriers 
and then infected with the MV strain Leningrad-16. 
Although the titers from roller bottle and microcarrier 
cultivation were within the same range, slightly higher 
virus titers were reached in roller cultures.  
 MV production with three different microcarriers 
(Cytodex 2, Micarcel G and Cytolar 2) had been 
investigated with quail embryo cells, as well (Sidorenko et 
al., 1989). With Cytodex 2 carriers, the maximum virus 
titer (6 × 105 TCID50 mL−1) was reached on day 5 p.i.; 
afterwards, the virus titer decreased. With Micarcel G 
carrier, the highest maximum titer (8×105 TCID50 mL−1) 
was observed on day 4 p.i. For these microcarriers, the 
maximum MV titer remained constant for about 2 days 
and decreased following day 6 p.i. The lowest virus yield 
was measured on Cytolar 2 microcarriers. A maximum 
titer was reached at day 7 p.i. (4×105 TCID50 mL−1) and 
decreased thereafter. With microcarrier cultivation, a 
twofold enhancement of virus yields was obtained at best 
compared to roller cultures, reaching maximal production 
rates of 4.5-6.4 TCID50 per cell. However, the virus 
production time and the harvest time was shortened with 
microcarrier systems. Furthermore, it was reported that MV 
yields could not be increased by higher microcarrier 
concentrations or cell densities. Sidorenko et al. (1989) 
further addressed the problem of determining the viable cell 
number after infection with MV. The cell number switched 
back and forth during MV production and determination of 
viable cell numbers by trypan blue exclusion was suggested 
to be not an adequate method. Since cells, which are stained 
blue, are supposed as dead, these cells could still release 
virus for an unknown time (Sidorenko et al., 1989).  
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Table 3. MV production performed with host cell cultivation on microcarrier. The respective bioreactor system, microcarrier and cell 
lined used are presented. 
    max. Titer (×106   
Culture system Microcarrier Cell line MV strain TCID50/mL) Ref. 
Spinner bottles Cytolar-2 quail embryo cells Leningrad 16 3.0 (Boriskin et al., 1988) 
 Cytodex 2 quail embryo cells Leningrad 16 0.6 (Sidorenko et al., 1989) 
 Micarcel G quail embryo cells Leningrad 16 0.8 
 Cytolar 2 quail embryo cells Leningrad 16 0.4  
 Cytodex 1 MRC-5 AIK-C 100,000.0  (Trabelsi et al., 2010) 
Bioreactor (STR) Cytodex 1 MRC-5 AIK-C 40,000.0 (Trabelsi et al., 2010) 
 Cytodex 1 MRC-5 AIK-C 10.0  (Trabelsi et al., 2012) 
 Cytodex 1 Vero Edmonston 50 .0 (Mendonca et al., 1994) 
 
 In another report, spinner flask cultures of MRC-5 
cells were cultivated on Cytodex 1 microcarriers (Trabelsi 
et al., 2010). In spinner flasks, the highest cell 
concentration was reached after 5 days of culture, which 
was chosen as time of infection. One day after infection 
with the AIK-C strain, the virus titer increased 
continuously until 6 days p.i. and reached a maximum titer 
of 1×1011 TCID50mL−1 (Trabelsi et al., 2010).  
1.17. Bioreactor Cultivation  
 First data concerning MV production in a bioreactor 
were published in 1994 using an STR (Mendonca et al., 
1994). MV was amplified on MRC-5 cells in an STR 
grown on Cytodex 1 microcarriers (Trabelsi et al., 2010), 
but also on a ready-to-use disposable fixed bed system 
(BelloCell) in Minimal Essential Medium (MEM) and 
0.2% Bovine Serum Albumin (BSA). In the STR, the 
TCID50 per cell and day was at minimum 15 times 
lower than in the BelloCell System (125 and 1,900 
TCID50 per cell and day, respectively). Shear stress 
was suggested to reduce the production yield in the 
STR (Trabelsi et al., 2010). 
 Taken the available data together, spinner or 
bioreactor cultivations are sufficient systems for MV 
production. Although MV yields were not always higher 
compared to T-flaks or roller bottles, the bioreactor 
system could still be advantageous considering the 
possibility of in-process control and direct regulation of 
e.g., pH and oxygenation. Additionally, serial harvesting 
could easily be automated. With further optimization of 
bioreactor cultivation, these systems seem to be very 
promising. MV yields produced with host cells cultivated 
on microcarriers in either spinner bottles or bioreactors 
are summarized in Table 3. 
1.18. Impact of Variations in Culture Modes 
on Measles Virus Production  
 Controlled culture systems can work in different 
culture modes. This includes variation in temperature, 
stirrer speed, or different feeding and harvesting 
strategies, which all could influence virus stability and 
cell growth. The impact of the parameters temperature, 
shear force, feeding and serial harvests have already 
been investigated. 
1.19. Impact of Culture Temperature  
 The various Edmonston derived vaccine strains have 
been further attenuated by additional passages in chicken 
embryo fibroblasts at a reduced temperature (32°C) 
(Katz, 2009). In some studies MV were also produced at 
lower temperature (Kohn, 1962; Boriskin et al., 1988; 
Mendonca et al., 1994; 2002), but MV production at 
37°C is common as well (Black, 1959; Shishido et al., 
1967, Nakai et al., 1969; Romano and Scarlata, 1973; 
Brandriss et al., 1982). Consequently, the impact of the 
cultivation temperature during MV production has 
already been evaluated. 
 Amplification of attenuated and virulent Edmonston 
strains on BSC-1 cells has been reported to be similar at 
34°C or 37°C (Rapp, 1964). A further comparative study 
of AIK-C strain MV production in MRC-5 cells at 34°C 
or 36°C in spinner cultures revealed slightly higher cell 
numbers with a cultivation temperature of 34°C, but MV 
titers were similar at both temperatures, again (Trabelsi 
et al., 2010). 
 MV Hallé and Edmonston strains produced at 
33°C or 37°C in Vero cell monolayers resulted in 
higher yields for the Hallé strain at 33°C. For the 
Edmonston strain, the yield was initially higher at 
37°C, but the overall yield was better at 33°C, when a 
longer production phase was feasible (four instead of 
two days). For both virus strains, the cultivation at 
37°C had to be terminated at least two days earlier 
than those at 33°C. This effect was supposed to be 
caused by the lytic nature of MV, which seems to be 
more intensive at higher temperatures (Scott and 
Choppin, 1982).  
 In HeLa cells MV yields were up to three folds 
higher (two log10 units) at 32.5°C than at 37°C. 
Additionally, the author demonstrated that higher yields 
were not due to temperature sensitivity. The titers of 20 
virus clones grown at 32.5°C were nearly the same (+/- 
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10%) when plated at 32.5 and 37°C. Thus, it was 
suggested that host cell factors, such as protein synthesis, 
or a temperature-dependent host cell protease needed for 
the processing of virus polypeptides could be altered at 
the different temperatures (Udem, 1984). 
1.20. Impact of Shear Forces  
 Mechanical shear forces have been published to 
increase MV yield from static monolayer cultures. 
Vigorous agitation could raise the virus titer about 2.5-
12.5-fold in the supernatant. Since the mechanical forces 
did not increase cellular contaminants in the supernatant, 
it was suggested that the increase could be due to MV 
particles, whose budding was assisted by the help of the 
mechanical forces. As this vigorous agitation was 
performed in static cultures, higher virus yields in 
bioreactor cultivations with permanent shear forces could 
be suggested (Wechsler et al., 1985). However, the 
agitation in static cultures was performed for the short 
time of harvest and not extensively during cultivation, 
thus it remains unclear, which effect a durable shear 
force during the whole cultivation period, as found in 
bioreactor systems, has got. Additionally, as serum is a 
protective agent concerning shear stress, it should be 
noted that the medium in the T-flasks had been replaced 
with serum-free medium 12-18 hours prior to the harvest 
(Wechsler et al., 1985). 
1.21. Impact of Culture Mode 
 Repeated batch and perfusion mode have been 
compared in an STR (Trabelsi et al., 2010). These 
data revealed an approximately 6-fold higher virus 
yield in the repeated batch mode (125 TCID50 per cell 
and day), compared to the perfusion mode (21 TCID50 
per cell and day). 
 In another study it has been demonstrated, that 
appropriate feeding of the cells is advantageous for MV 
production (Mendonca et al., 2002). The analysis of the 
effects of glutamine or galactose feeding on the growth 
of Vero cells on Cytodex 1 microcarriers and subsequent 
MV production are summarized in Table 4 (Mendonca 
et al., 2002). MV yields were successfully raised by 
increasing the cell number by feeding, as well. Infection 
on the fourth day of cultivation, when the batch 
cultivation was terminated, resulted in a virus titer of 
5×106 TCID50 mL−1 5 days post infection. Without 
feeding, the cell number was drastically reduced until the 
12th day of cultivation and infection of these cells 
resulted in a low virus yield 5 days p.i. However, with 
galactose and glutamine feeding, infection of 12 days old 
cultures resulted in a titer of 8×106 TCID50 mL−1, again 
on day 5 p.i. The feeding resulted in a very significant 
reduction of the percentage of apoptotic cells on the day 
of infection. As illustrated in Table 4, the virus titer per 
cell increases with a reduced rate of apoptotic cells. 
These data reveal that an optimized production process 
for the cell line could lead to higher MV production rates 
(Mendonca et al., 2002). 
1.22. Impact of Harvesting Strategies 
 Overall virus yields have been reported to be 
enhanced by repeated harvest of released virus, when 
conditioned medium from infected monolayers has been 
replaced with fresh medium (Scott and Choppin, 1982). 
When considering the comparatively low half-life of the 
virus at 37°C (i.e., 2 h) (Black, 1959), this procedure 
might be promising. Interestingly, only slightly lower 
virus titers in the culture medium have been reported, 
when the medium was fully exchanged one hour prior to 
sampling (Black, 1959). This indicates some kind of 
equilibrium between release and decay and therefore 
suggests that a considerable amount of virus is wasted if 
serial harvesting from the culture medium is omitted. 
The effect of harvest time has also been investigated 
(Scott and Choppin, 1982). A single harvest on the fourth 
day p.i. resulted in yields of 28 pfu per cell for 
extracellular and 188 pfu per cell for cell-associated virus, 
which represents a ratio of released-to-cell-associated 
virus of about 1:6.7. Increasing the numbers of virus 
harvests from the supernatant resulted in higher released 
to cell-associated ratios for cumulative yields, respectively 
in values of 1:3.6 for one additional harvest on day 2 p.i. 
and 1:2.4 for three additional harvests on days 2.5, 3 and 
3.5 p.i. With a total of 4 harvests, maximum numbers of 
270 and 651 pfu per cell for extracellular and cell-
associated virus, respectively, have been determined. This 
positive effect appeared always, when the time point of 
the first harvest was chosen at day 2 p.i. or later (Scott and 
Choppin, 1982). Daily harvesting of extracellular virus 
starting 24 h. p.i. resulted in reduced yields of 22 and 58 
pfu cell−1 for extracellular and cell-associated virus titers, 
respectively. The authors suggested that under these 
circumstances the medium removal one day after 
inoculation did not allow enough cells to become initially 
infected (Scott and Choppin, 1982).  
 
Table 4. Effect of feeding on MV yield and cell viability, summary of data published by Mendonca et al.  (2002). Presentation of the effect of 
feeding on apoptosis of cells and measles virus yield 
 Cell density at time Apoptotic cells at  MV yield 5 days p.i. 
 of infection day of infection  ------------------------------------------------------------ 
Day of infection (×105 cells mL−1) (% of cells) Feeding a (×106 TCID50 mL−1) (TCID50 per cell b) 
4 5.1 2 no 5 9.8 
12 3 88 no 0.00052 0.002 
12 9.2 12 yes 8 8.7 
a; Fed with 4 mM galactose and 2 mM glutamine at days 4, 6, 8 and 10; b: Correlated to the cell number at time of infection 
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Table 5. Summary of published data for MV production. MV yields with respect to the MOI, the scale or mode of cultivation, virus strains and cell 
lines are presented. For better comparability, titers in pfu were converted in TCID50 by multiplication with the factor 0.7 
Max. Titer (×   
106  Cells/ Cell-associated Scale/ mode 
TCID50/mL) MOI MV strain /extracellular MV of production Remarks Ref. 
- 1 CV-1/ not specified extracellular 150 cm² T-flasks (33°C p.i.), increased yield (Wechsler et al., 1985) 
     by vigorous agitation 
0.046 2-5 HeLa/ DP line of the - 16 cm rubber stoppered examining amino acid 
  Edmonston strain  bottles, roller drum deprivation during (Romano and Scarlata, 1973) 
     MV growth, (37°C p.i.) 
0.36 0.01 quail embryo cells/ - siliconized 1 L spinner, Cytodex 2, Micarcel G, 
  Leningrad-16 strain  working volume 0.5 L Cytolar 2 (each with 20 g/L) (Sidorenko et al., 1989) 
0.56 0.025, KB cells / Edmonston cell-associated / petri dishes (50  (37°C p.i.), MV inactivation (Kohn and Yassky, 1962) 
 0.01 strain extracellular mm dish) kinetics at 37°C 
0.63 1.5 Hep-2/ Edmonston cell-associated / - growth curves of MV, 
  strain extracellular   characterization of temperature (Black, 1959) 
     and pH-sensitivity, (37°C p.i.) 
3 1.4 Vero/ TYCSA strain  extracellular roller tubes with 1 (37°C p.i.) (Shishido et al., 1967) 
  (variant of the    mL fluid 
  Toyoshima strain) 
8 0,1 Vero / Edmonston extracellular T-flasks or spinner Cytodex 1 (2 g/L), 
  strain  bottles at 60 rpm, cells are fed with galactose and  (Mendonca et al., 2002) 
     glutamine, (33°C p.i.) 
8.6 0.02 U937 / Edmonston cell-associated / suspension cells, (37°C p.i.) (Brandriss et al., 1982) 
  strain extracellular,  spinner 
   daily 
10 0.03 quail embryo cells / - stationary monolayer, MC: Cytolar 2, (33°C p.i.) (Boriskin et al., 1988) 
  Leningrad-16 strain  roller or microcarrier 
    cultures (0.5 L Techno 
    cell stirrer bottles) 
10 0.01, MRC-5/ AIK-C  - STR 3 L working Cytodex 1(3 g/L), (Trabelsi et al., 2012) 
 0.001, strain  volume MOI variation, different 
 0.005    culture modes 
14 0.01-1, BSC-1, primary rhesus cell-associated / 4-ounce prescription (37°C p.i.) (Nakai et al., 1969) 
 10 monkey kidney cells/ extracellular bottles. 
  Edmonston 
70 0.01-1 HeLa/Edmonston cell-associated / suspension cells (37 and 32.5°C) (Udem, 1984) 
   extracellular 
170 0.5 Vero/Edmonston cell-associated / Celligen cell culture Cytodex 1 (Mendonca et al., 1994) 
  strain extracellular, until 3.7 L, 60 rpm, for (2 g/L), (33°C p.i.) 
   cytopathic effect comparison also  
   (96-120 h p.i.) roux bottles` 
230 0.1, 10 MA160, Vero/ cell-associated/ monolayers (75 cm²) - (Baczko and Lazzarini, 1979) 
  Edmonston strain extracellular and suspension cultures 
400 0,001-10 HEp-2, AV3, BHK- mainly extracellular flasks, monolayers investigation of: (Scott and Choppin, 1982) 
  21, PK-15, MDCK,    FCS, temperature (33 
  Vero, BGMK / Halle   and 37°C), buffer, insulin, 
  or Edmonston strain   virus strain, cell line, MOI 
100,000 0.01 MRC-5/ AIK-C strain - packed bed (BelloCell Cytodex 1(3 g/L), various (Trabelsi et al., 2010) 
    disposable); STR 2 L  cell culture modes, comparison 
    (working volume 1.2 L); of virus titers and cell 
    spinner (working concentrations, spinner: 
    volume 0.5 L) (36 and 34°C p.i.), bioreactor: 
     (34°C p.i.) 
 
However, this interpretation stays in contrast to reports 
describing that MV inactivation proceeds within few 
hours and first progeny virus appears already 12 h after 
infection (Black, 1959). 
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 The few available data for MV production suggest 
that feeding and repeated harvesting are advantageous for 
high virus yields. The culture temperature and shear stress 
can affect the total yield ambivalently. However, more 
detailed studies of these parameters might be considered.  
1.23. Summary  
 Table 5 summarizes the currently available data 
for MV production with respect to the MOI, the scale 
or mode of cultivation, virus strains and cell lines. For 
better comparability, titers in pfu were converted in 
TCID50 by multiplication with the factor 0.7. 
2. CONCLUSION 
 Due to its ability of efficient tumor cell killing, MV 
has been identified as a potential oncolytic virus. Thus, 
there is considerable interest of a scalable, reproducible, 
optimized, standardized and automated production 
process for this promising agent.  
 Since being established for several decades, MV 
production for vaccination purposes is not exploiting the 
technical possibilities offered by modern cell culture 
technologies. However, simply up-scaling of the robust 
and established traditional technologies may be difficult 
when trying to push the viral yield by a factor of up to a 
million. In addition, potential second generation MV 
agents with modified tumor-selective cell-entry do most 
likely not infect traditional cell substrates used for 
producing parental vaccine MV. 
 Additionally, economic considerations play an 
important role for optimizing a biomedical production 
process. A great factor concerning costs is the scale of a 
process. It is a big difference whether production is 
performed in static systems as T-flasks and roller bottles, 
or in a bioreactor. For example, a bioreactor cultivation 
with 1 L working volume and Cytodex 1 microcarriers at a 
concentration of 3 g L−1 confers the same surface area for 
cell growth as 44 T-flasks (each 300 cm² surface) or 
approx. 16 roller bottles (each 850 cm²). By this example, 
it is quite obvious that requirements for media, space and 
manpower are much less for the bioreactor cultivation. 
Bioreactor cultivation would be a good alternative to 
generate the amounts of MV needed for a routine 
therapeutic cancer treatment, since all other (including 
traditional) culture systems may be hard to scale up or 
even do not provide the necessary cell numbers and 
densities. The feasibility of bioreactor cultivation systems 
for MV production has already been demonstrated 
(Mendonca et al., 1994; Mendonca et al., 2002; Trabelsi et 
al., 2010). As promising the bioreactor cultivation is, there 
is unfortunately only little data available referring to MV 
production in such systems. Additionally, further aspects 
like oxygen demand or shear stress have to be considered.  
 An optimization of different factors (temperature, 
MOI, addition of salts and repeated harvesting) has 
already been investigated in the past. Some of these 
factors are very important, as e.g., the relative high 
sensitivity of the MV to temperatures (Black, 1959), or 
the potential to protect MV particles or promote 
infectivity by certain salts, respectively (Rapp et al., 
1965; Boriskin et al., 1988). Referring to extracellular 
virus yields, the temperature sensitivity of the virus 
could be a critical parameter, as well. Virus in the 
supernatant is inactivated by elevated temperatures, 
which could be a reason for cell-associated virus yields 
being almost always reported to be higher than 
extracellular yields (Black, 1959; Rapp, 1964; Shishido 
et al., 1967; Nakai et al., 1969; Mendonca et al., 1994). 
Since studies utilizing lowered temperatures during MV 
production revealed only slightly higher or similar virus 
titers (Rapp et al., 1965; Scott and Choppin, 1982; 
Trabelsi et al., 2010), this attempt may not be too 
promising. Having this in mind, it could be advantageous 
to integrate repeated or even continuous harvesting of 
extracellular virus with immediate cooling of the 
harvested virus into the process. Hence cell-associated 
virus can only be harvested once, total amounts of 
released virus from repeated harvests could exceed the 
amounts of cell-associated virus. 
 The addition of FCS provides serum proteins and 
essential amino acids for virus production. Accordingly, 
MV yields were almost always higher with serum 
supplemented medium (Scott and Choppin, 1982). 
Addition of serum is a critical factor, as it is of an 
unknown composition and therefore limits the 
reproducibility of a process. Furthermore, serum 
complicates the purification steps following production, 
since the product should be free of any contaminations 
when applied to human patients e.g., in cancer therapy. 
Thus, modern cultivation systems tend to rely on serum 
free cultivation, with complete serum free media being 
commercially available that can support comparable 
growth of host cells (Rourou et al., 2007) and therefore 
high MV yields, too. Regarding medium composition, 
specific amino acids revealed a strong impact on MV 
growth (Romano and Scarlata, 1973) and appropriate 
feeding of Vero cells prior to MV infection also 
increased the MV yields (Mendonca et al., 2002). 
However, the available data also indicate that a lot more 
factors influence MV production, accumulating in the 
need for detailed kinetic studies. 
 Besides exogenous factors the virus-cell system 
has to be optimized, as well. This includes that certain 
MV strains are adapted for growth in specific cell 
lines. Additionally, the ratio of virus per cell (MOI) is 
an important factor to consider. A low MOI around 
0.01 reproducibly resulted in the highest MV titers 
(Nakai et al., 1969; Baczko and Lazzarini, 1979; Scott 
and Choppin, 1982), but causes an elongated time of 
cultivation. Furthermore, high MOI reduced budding 
of virus particles (Nakai et al., 1969) and thus shifts 
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the balance to cell-associated virus, which is more 
difficult to purify.  
 Processing for scale up systems in the field of cell 
culture has been performed over the past 50 years. 
Dynamic cultivations for mammalian cells have been 
operated from spinner systems up to bioreactors with 
working volumes up to several hundreds of liters (Eibl et 
al., 2008). Development of microcarrier system made 
such cultivation modes possible for adherent cell 
cultures, as well. Moreover, the bioreactor cultivation 
should be an easy method to improve the space-time-
yield and the microcarrier system seems to be a proper 
operation mode for the production of MV (Boriskin et 
al., 1988; Sidorenko et al., 1989; Mendonca et al., 
1994; Mendonca et al., 2002; Trabelsi et al., 2010). 
Much effort in standardized bioreactor cultivation 
with mammalian cells has been done. The growing use 
of disposable systems such as single-use bags for 
bioreactors, sensors, sampling or seed inoculums 
further advanced the cultivations (Eibl et al., 2008). 
 For MV production, further efforts should 
concentrate on the following developments: 
 
• A production process, which enables an easy scale 
up of the respective microcarrier systems 
• As FCS is an undefined substance, MV should be 
produced in serum free medium 
• Appropriate feeding of the cells during growth and 
virus production, which is based on detailed kinetic 
studies 
• An established offline analytic would help 
integrating methods for online measurements and 
process automation 
• The integration of an automated tool for serial or 
even continuous harvests 
 
 Solving these tasks should allow the set-up of an 
optimized, versatile production process, resulting in 
measles virus preparations intended for the use as 
oncolytic agents in the desired quality and quantities 
under affordable conditions. 
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